Notification regarding unquoted securities - IBX
Released
Released
Announcement PDF
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Announcement Summary
Entity name
IMAGION BIOSYSTEMS LIMITED
Date of this announcement
Friday December 17, 2021
The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being
quoted on ASX until the restriction ends
Total number of +securities to be issued/transferred
ASX +security
code
Security description
Total number of
+securities to be
issued/transferred
Issue date
New class - code
to be confirmed
6,000,000 FY21 Performance Options exercisable
at $0.0872, vesting and expiring on different
terms.
6,000,000
14/12/2021
New class - code
to be confirmed
1,500,000 Unlisted Options exercisable at
$0.0872, vesting monthly over 3 years varying
expiry dates
1,500,000
14/12/2021
New class - code
to be confirmed
9,000,000 FY21 Performance Rights vesting
during a 4 year period subject to performance
milestones.
9,000,000
14/12/2021
Refer to next page for full details of the announcement
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
1 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 1 - Entity and announcement details
1.1 Name of entity
IMAGION BIOSYSTEMS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
1.2 Registered number type
Registration number
ACN
616305027
1.3 ASX issuer code
IBX
1.4 The announcement is
New announcement
1.5 Date of this announcement
17/12/2021
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
2 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being
quoted on ASX until the restriction ends
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and
which:
does not have an existing ASX security code ("new class")
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
3 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX
in an Appendix 3B
New +securities issued under an +employee incentive scheme
ASX +security code
+Security description
New class - code to be confirmed
6,000,000 FY21 Performance Options exercisable at
$0.0872, vesting and expiring on different terms.
+Security type
ISIN code
Other
Date the +securities the subject of this notification were issued
14/12/2021
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate?
Yes
Provide details of the KMP or +associates being issued +securities.
Name of KMP
Name of registered holder
Number of +securities
Yalia Jayalakshmi
Yalia Jayalakshmi
6,000,000
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being
issued.
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
or a summary of the terms
A summary of the terms of the Employee
Incentive Scheme were provided in the
Notice of Annual General Meeting announced
to the ASX on 19 June 2020
https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4
j96kz.pdf
Any other information the entity wishes to provide about the +securities the subject of this notification
6,000,000 Options exercisable at $0.0872, vesting and expiring:
-1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company secures decision
enabling data package from a minimum 12-15 subjects enrolment in the phase 1 clinical study to enable Go/No Go
development decision for the MagSenseĀ® HER2 product candidate; options will expire on 30 Nov 2025;
-1,000,000 Options will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company completes the
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
4 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
MH2TR Phase 1 study or submits a regulatory package in the US or EU or another country of interest to expand the
current Phase 1 study; options will expire on 30 Nov 2025;
-1,000,000 Options vest on 30 Nov 2022, expire on 30 Nov 2027;
-1,000,000 Options vest on 30 Nov 2023, expire on 30 Nov 2028;
-1,000,000 Options vest on 30 Nov 2024, expire on 30 Nov 2029;
-1,000,000 Options vest on 30 Nov 2025, expire on 30 Nov 2030.
Vesting of the options is subject to continuous employment.
Issue details
Number of +securities
6,000,000
New +securities issued under an +employee incentive scheme
ASX +security code
+Security description
New class - code to be confirmed
1,500,000 Unlisted Options exercisable at $0.0872, vesting
monthly over 3 years varying expiry dates
+Security type
ISIN code
Other
Date the +securities the subject of this notification were issued
14/12/2021
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate?
No
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being
issued.
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
or a summary of the terms
A summary of the terms of the Employee
Incentive Scheme were provided in the
Notice of Annual General Meeting announced
to the ASX on 19 June 2020
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
5 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4
j96kz.pdf
Any other information the entity wishes to provide about the +securities the subject of this notification
1,500,000 Unlisted Performance Options exercisable at $0.0872, vesting monthly over 3 years with varying expiry dates
between 31 December 2024 and 30 November 2027. The vesting of the options is subject to continuous employment.
Issue details
Number of +securities
1,500,000
New +securities issued under an +employee incentive scheme
ASX +security code
+Security description
New class - code to be confirmed
9,000,000 FY21 Performance Rights vesting during a 4
year period subject to performance milestones.
+Security type
ISIN code
Other
Date the +securities the subject of this notification were issued
14/12/2021
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate?
Yes
Provide details of the KMP or +associates being issued +securities.
Name of KMP
Name of registered holder
Number of +securities
Yalia Jayalakshmi
Yalia Jayalakshmi
9,000,000
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being
issued.
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
Notification of Issue, Conversion or Payment up of Unquoted
6 / 11
Equity Securities
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme
or a summary of the terms
A summary of the terms of the Employee
Incentive Scheme were provided in the
Notice of Annual General Meeting announced
to the ASX on 19 June 2020
https://www.asx.com.au/asxpdf/20200619/pdf/44jsf59t4
j96kz.pdf
Any other information the entity wishes to provide about the +securities the subject of this notification
Vesting conditions:
-1,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company
submits a regulatory package (IND/IDE/CTA or equivalent) in the US or EU for investigational use of at least one product
candidate;
-2,000,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company
obtains US or EU regulatory investigational use clearance to proceed to patient enrolment for at least one product
candidate;
-2,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company
achieves a market capitalisation of at least $250 million for a continuous period of at least 20 trading days; and
-3,500,000 Performance Rights will vest if, during the 4 year period from 1 Dec 2021 to 30 Nov 2025, the Company
obtains regulatory agreement (FDA/EU or another country of interest) for a pivotal or phase 2b/3 protocol (such as FDA
EOP2 meeting minutes).
Issue details
Number of +securities
9,000,000
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
7 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
8 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of
the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one
application for quotation/issuance currently with ASX for processing.)
4.1 Quoted +Securities (Total number of each +class of +securities quoted)
Total number of
+securities on issue
ASX +security code and description
IBX : ORDINARY FULLY PAID
1,121,018,534
IBXOA : OPTION EXPIRING 28-APR-2023
233,501,933
4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)
Total number of
+securities on issue
ASX +security code and description
IBXAAD : OPTION EXPIRING 30-NOV-2026 EX $0.14
1,000,000
IBXAAE : OPTION EXPIRING 30-NOV-2027 EX $0.14
1,000,000
IBXAAF : OPTION EXPIRING 30-NOV-2028 EX $0.14
1,000,000
IBXAW : OPTION EXPIRING 24-JUN-2024 EX $0.028
2,150,000
IBXAX : OPTION EXPIRING 22-AUG-2024 EX $0.06
300,000
IBXAY : OPTION EXPIRING 07-OCT-2024 EX $0.06
200,000
IBXAZ : OPTION EXPIRING 20-SEP-2024 EX $0.06
100,000
IBXAAA : OPTION EXPIRING 01-MAY-2026 EX $0.028
3,250,000
IBXAAB : OPTION EXPIRING 01-MAY-2027 EX $0.028
3,250,000
IBXAAC : OPTION EXPIRING 01-MAY-2028 EX $0.028
2,000,000
IBXAE : PERFORMANCE RIGHTS
10,000,000
IBXAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
7,150,000
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
9 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
IBXAAG : OPTION EXPIRING 31-MAY-2029 EX $0.115
200,000
New class - code to be confirmed : 6,000,000 FY21 Performance Options exercisable at
$0.0872, vesting and expiring on different terms.
6,000,000
New class - code to be confirmed : 1,500,000 Unlisted Options exercisable at $0.0872,
vesting monthly over 3 years varying expiry dates
1,500,000
New class - code to be confirmed : 9,000,000 FY21 Performance Rights vesting during a 4
year period subject to performance milestones.
9,000,000
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
10 / 11
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue
did not need any security holder approval under Listing Rule 7.1?
Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
13
Notification of Issue, Conversion or Payment up of Unquoted
Equity Securities
11 / 11
Share your feedback
Discover